The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed New Long Term Incentive Plan

11 Oct 2010 16:00

RNS Number : 2047U
PuriCore Plc
11 October 2010
 



PuriCore plc  

Proposed New Long Term Incentive Plan and Proposed Amendment to the Existing Option Plan and Notice of General Meeting

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 11 October 2010 - PuriCore plc (LSE: PURI) ("PuriCore" or the "Company"), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that it is proposing a new Long Term Incentive Plan ("LTIP") and an amendment to the Company's Executive Omnibus Incentive Plan (the "Option Plan").

 

A circular is expected to be posted today to Shareholders by the Company that contains details of the LTIP and the associated proposed change to the Option Plan (the "Circular"). The Directors are seeking approval of the LTIP and the amendment to the Option Plan at a General Meeting to be held at 9.00 a.m. at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD on 29 October 2010.

 

PuriCore Value Sharing Plan (LTIP)

The LTIP allows the creation of an award pool of 15% of the amount by which the market capitalisation of the Company exceeds £35 million on 30 September 2012. This award pool will be allocated amongst the participants at a pre-determined rate and is intended to be satisfied through a combination of new ordinary shares and cash. To implement the LTIP, the Option Plan is proposed to be amended to exclude the issue of any share awards under the LTIP from the Option Plan dilution limit.

 

PuriCore will realise short-term cash savings from the implementation of the LTIP as some participants are accepting reductions in cash-based compensation-for the term of the LTIP-in exchange for participation in the LTIP. These reductions include foregoing employer retirement plan contributions and waiving rights to the annual bonus scheme, for those participants who are entitled to these benefits, and certain participants taking an approximate 17% reduction in basic salary. Further, all participants must waive their rights to existing share option grants, whether vested or unvested.

 

A summary of the LTIP and a summary of the proposed amendment to the Option Plan is set out in the Circular.

 

Background to the PuriCore Value Sharing Plan

The Remuneration Committee of the Board of Directors (the "Remuneration Committee") believes the LTIP is an appropriate tool to motivate the participants to achieve the Company's sales growth and profitability goals, and to deliver significant value to shareholders in terms of market capitalisation increase. The Remuneration Committee is confident that the senior executive team charged with delivering the Company's goals is focused and that the strategies being implemented should allow the Company to meet its goals on an accelerated basis. Aligning the senior executive remuneration strategy with the Company's business goals and with the interests of shareholders is critical. The Remuneration Committee believes the LTIP does this in the following ways:

 

·; incentivises the participants to focus on strategies and tactics with a common goal of creating shareholder wealth by increasing market capitalisation;

 

·; establishes a challenging market capitalisation hurdle of £35 million (compared with the current market capitalisation of approximately £13 million) below which participants receive no pay-out;

 

·; provides a short-term (24-month) period for delivering on the Company's goals; and

 

·; offers flexibility in the type of senior executive remuneration (shares or cash), which the Remuneration Committee can utilise based on the financial and cash position of the Company at the time of the award.

 

A copy of the Circular and related form of proxy have been submitted to the National Storage Mechanism and will shortly be available for inspection. The Notice of General Meeting will shortly be available on the Company's website.

 

Enquiries:

 

Financial Dynamics

PuriCore

Susan Quigley

Chris Wightman

Ben Brewerton

Executive Chairman

+44 (0) 20 7831 3113

+44 (0) 20 7290 3440

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALEFFSEEFFF
Date   Source Headline
1st Feb 20199:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
31st Jan 201910:06 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
29th Jan 201910:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Jan 20198:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
22nd Jan 20199:10 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
14th Jan 20199:44 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
11th Jan 20199:39 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
8th Jan 201910:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Jan 20199:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
3rd Jan 20199:53 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Jan 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Dec 201810:47 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
24th Dec 201810:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 20188:54 amRNSForm 8.3 - Realm Therapeutics plc
19th Dec 201810:27 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Dec 20189:35 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
10th Dec 20181:20 pmRNSForm 8.3 - Realm Therapeutics plc
10th Dec 201810:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Dec 201810:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Dec 20189:56 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Dec 201812:20 pmRNSForm 8.5 (EPT/RI) Realm therapeutics
3rd Dec 201811:20 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
30th Nov 20184:08 pmRNSHolding(s) in Company
30th Nov 20181:18 pmRNSForm 8.3 - Realm Therapeutics plc
30th Nov 201811:39 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 201811:58 amRNSHolding(s) in Company
29th Nov 201811:13 amRNSForm 8.3 - Realm Therapeutics plc
29th Nov 20189:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 20187:00 amRNSUpdate on Strategic Review
28th Nov 201810:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Nov 20189:53 amRNSForm 8.3 - Realm Therapeutics plc
27th Nov 20186:28 pmRNSForm 8.3 - Realm Therapeutics plc
26th Nov 201811:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
26th Nov 20188:41 amRNSForm 8.3 - Realm Therapeutics plc
12th Nov 20188:32 amRNSForm 8.5 (EPT/RI) Realm therapeutics
7th Nov 20185:14 pmRNSHolding(s) in Company
7th Nov 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Nov 20189:03 amRNSForm 8.3 - Realm Therapeutics plc
6th Nov 201810:36 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Nov 201811:31 amRNSForm 8.3 - Realm Therapeutics plc
31st Oct 20189:04 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Oct 20189:34 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Oct 201810:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Oct 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
16th Oct 20189:31 amRNSForm 8.5 (EPT/RI) Realm therapeutics
15th Oct 20189:34 amRNSForm 8.3 - Realm Therapeutics plc
15th Oct 20189:24 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Oct 20188:58 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.